Oscar P. J. van Linden

Oscar P. J. van Linden

Auto-generated profile, based on publicly available information

Oscar P. J. van Linden

Division of Medicinal Chemistry, Amsterdam Institute of Molecular and Life Sciences, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
OLOscar P. J. van Linden
Oscar P. J. van Linden
AKAlbert Kooistra
Albert Kooistra
RLRob Leurs
Rob Leurs
IEIwan de Esch
Iwan de Esch
CGChris De Graaf
Chris De Graaf

22 October 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AKAlbert Kooistra
Albert Kooistra
GKGeorgi K. Kanev
Georgi K. Kanev
OLOscar P.J. van Linden
Oscar P.J. van Linden
RLRob Leurs
Rob Leurs
IEIwan de Esch
Iwan de Esch
CGChris De Graaf
Chris De Graaf
Protein kinases play a crucial role in cell signaling and are important drug targets in several therapeutic areas. The KLIFS database contains detailed structural kinase-ligand interaction information derived from all (>2900) structures of catalytic domains of human and mouse protein kinases deposited in the Protein Data Bank in order to provide insights into the structural determinants of kinase-ligand binding and selectivity. The kinase structures have been processed in a consistent manner by systematically analyzing the structural features and molecular interaction fingerprints (IFPs) of a predefined set of 85 binding site residues with bound ligands. KLIFS has been completely rebuilt and extended (>65% more structures) since its first release as a data set, including: novel automated annotation methods for (i) the assessment of ligand-targeted subpockets and the analysis of (ii) DFG and (iii) αC-helix conformations; improved and automated protocols for (iv) the generation of sequence/structure alignments, (v) the curation of ligand atom and bond typing for accurate IFP analysis and (vi) weekly database updates. KLIFS is now accessible via a website (http://klifs.vu-compmedchem.nl) that provides a comprehensive visual presentation of different types of chemical, biological and structural chemogenomics data, and allows the user to easily access, compare, search and download the data.

1 January 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
OLOscar P.J. van Linden
Oscar P.J. van Linden
CFCarine Farenc
Carine Farenc
WZWillem H. Zoutman
Willem H. Zoutman
LHLiesbeth Hameetman
Liesbeth Hameetman
MWMaikel Wijtmans
Maikel Wijtmans
IEIwan de Esch
Iwan de Esch

16 August 2012 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
OLOscar P. J. van Linden
Oscar P. J. van Linden
MWMaikel Wijtmans
Maikel Wijtmans
LRLuc Roumen
Luc Roumen
LRLonneke Rotteveel
Lonneke Rotteveel
RLRob Leurs
Rob Leurs
IEIwan de Esch
Iwan de Esch

13 August 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
LBLars C. P. Binkhorst
Lars C. P. Binkhorst
IJIvana Josimovic
Ivana Josimovic
DVDaan de Vetten
Daan de Vetten
TNTyrone J. Nijman
Tyrone J. Nijman
NHNiels J. Hauwert
Niels J. Hauwert
RLRob Leurs
Rob Leurs
Despite the pharmacological relevance of the histamine H 1 receptor (H 1 R), the second most therapeutically targeted G protein-coupled receptor (GPCR), an effective photoswitchable ligand to optically control this receptor remains elusive.

29 January 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
TDTom Dekker
Tom Dekker
OLOscar P. J. van Linden
Oscar P. J. van Linden
HLHerman Lim
Herman Lim
MDMabel E. Dekker
Mabel E. Dekker
HVHenry F. Vischer
Henry F. Vischer
IEIwan de Esch
Iwan de Esch
Fragment-based drug discovery enables translation of novel (3D) chemistries into biologically relevant hit matter, as demonstrated by the identification and optimization of a cyclobutane-based 3D fragment into a potent histamine H 1 receptor ligand.